Finance

Lists
214450:KOSDAQ
PharmaResearch Co Ltd
â‚©386,500.00
+1.44%
(+5,500.00) 1D
Sep 4, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 214450...
Open
â‚©386,000
High
â‚©394,500
Low
â‚©375,000
Mkt. cap
4.02T
Avg. vol.
205.16K
Volume
55.76K
Dividend
0.96%
Quarterly dividend
â‚©925
Ex-dividend date
Dec 27, 2024
P/E ratio
23.68
52-wk high
â‚©696,000
52-wk low
â‚©255,000
EPS
â‚©16,318
Shares outstanding
10.39M
No. of employees
542
Open
â‚©386,000
High
â‚©394,500
Low
â‚©375,000
Mkt. cap
4.02T
Avg. vol.
205.16K
Volume
55.76K
Dividend
0.96%
Quarterly dividend
â‚©925
Ex-dividend date
Dec 27, 2024
P/E ratio
23.68
52-wk high
â‚©696,000
52-wk low
â‚©255,000
EPS
â‚©16,318
Shares outstanding
10.39M
No. of employees
542
About PharmaResearch Co Ltd
CEOJung Sangsoo
Employees542
Founded1993
Headquarters-
SectorBiotechnology
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
135.43B
143.35B
146.10B
178.70B
Cost of goods sold
26.28B
33.92B
33.17B
41.16B
Cost of revenue
26.28B
33.92B
33.17B
41.16B
Research and development expenses
8.23B
11.80B
10.10B
13.44B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
36.01B
42.78B
42.31B
54.78B
Operating expense
47.27B
59.58B
55.35B
71.01B
Total operating expenses
73.56B
93.50B
88.53B
112.17B
Operating income
61.87B
49.84B
57.57B
66.53B
Other non operating income
2.97B
-615.72M
-9.00B
8.57B
EBT including unusual items
64.83B
49.91B
68.02B
74.05B
EBT excluding unusual items
64.84B
50.89B
57.57B
75.11B
Income tax expense
13.97B
10.58B
19.27B
17.82B
Effective tax rate
21.56%
21.20%
28.33%
24.07%
Other operating expenses
290.06M
105.71M
540.02M
-212.36M
Net income
48.97B
32.57B
47.57B
56.57B
Net profit margin
36.16%
22.72%
32.56%
31.66%
Earnings per share
-
3.05K
4.24K
4.89K
Interest and investment income
-
5.81B
9.10B
-
Interest expense
-
-2.75B
-5.23B
-
Net interest expenses
-
3.06B
3.87B
-
Depreciation and amortization charges
1.46B
1.50B
1.55B
1.82B
EBITDA
65.89B
53.92B
61.77B
71.04B
Gain or loss from assets sale
-11.44K
-8.83M
-
-30.23M
AI content may include mistakes. Learn more
Google apps